LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

2.71 -1.81

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.68

Max

2.71

Galvenie mērījumi
By Trading Economics
Ienākumi	183K -27M
Darbinieki	166
EBITDA	9.4M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+158.3% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	65M 161M
Iepriekšējā atvēršanas cena	4.52
Iepriekšējā slēgšanas cena	2.71

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026. g. 13. marts 19:08 UTC

Galvenie ziņu notikumi

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

2026. g. 15. marts 23:45 UTC

Tirgus saruna

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026. g. 15. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026. g. 15. marts 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026. g. 15. marts 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026. g. 15. marts 22:37 UTC

Tirgus saruna

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026. g. 15. marts 22:18 UTC

Tirgus saruna

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 03:00 UTC

Galvenie ziņu notikumi

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026. g. 14. marts 15:00 UTC

Galvenie ziņu notikumi

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026. g. 14. marts 02:03 UTC

Peļņas

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026. g. 14. marts 01:32 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026. g. 14. marts 00:29 UTC

Iegādes, apvienošanās, pārņemšana

13D Filings -- Barrons.com

2026. g. 13. marts 22:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026. g. 13. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026. g. 13. marts 22:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026. g. 13. marts 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 20:02 UTC

Tirgus saruna

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026. g. 13. marts 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026. g. 13. marts 19:35 UTC

Galvenie ziņu notikumi

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

158.3% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 158.3%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.